{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T05:45:22Z","timestamp":1792129522974,"version":"4.4.0"},"reference-count":75,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100008884","name":"Edward P. Evans Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008884","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Hematology"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1053\/j.seminhematol.2026.04.003","type":"journal-article","created":{"date-parts":[[2026,4,19]],"date-time":"2026-04-19T14:49:11Z","timestamp":1776610151000},"page":"126-135","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Current landscape and future directions for treatment of accelerated-phase and blast-phase myeloproliferative neoplasms"],"prefix":"10.1053","volume":"63","author":[{"given":"Rohan K.","family":"Achar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3352-0902","authenticated-orcid":false,"given":"Jan Philipp","family":"Bewersdorf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1053\/j.seminhematol.2026.04.003_bib0001","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN","volume":"140","author":"D\u00f6hner","year":"2022","journal-title":"Blood"},{"issue":"7","key":"10.1053\/j.seminhematol.2026.04.003_bib0002","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","article-title":"The 5th edition of the World Health Organization classification of Haematolymphoid tumours: myeloid and histiocytic\/dendritic neoplasms","volume":"36","author":"Khoury","year":"2022","journal-title":"Leukemia"},{"issue":"16","key":"10.1053\/j.seminhematol.2026.04.003_bib0003","doi-asserted-by":"crossref","first-page":"2152","DOI":"10.1182\/blood.2020008109","article-title":"The pathobiology of thrombosis, microvascular disease, and hemorrhage in the myeloproliferative neoplasms","volume":"137","author":"Hasselbalch","year":"2021","journal-title":"Blood"},{"issue":"1","key":"10.1053\/j.seminhematol.2026.04.003_bib0004","first-page":"101","article-title":"Thrombotic and bleeding complications in classical myeloproliferative neoplasms","volume":"39","author":"McMahon","year":"2013","journal-title":"Semin Thromb Hemost"},{"issue":"2","key":"10.1053\/j.seminhematol.2026.04.003_bib0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.beha.2022.101372","article-title":"Addressing symptom burden in myeloproliferative neoplasms","volume":"35","author":"Tremblay","year":"2022","journal-title":"Best Pract Res Clin Haematol"},{"issue":"2","key":"10.1053\/j.seminhematol.2026.04.003_bib0006","doi-asserted-by":"crossref","DOI":"10.1016\/j.beha.2022.101379","article-title":"Accelerated and blast phase myeloproliferative neoplasms","volume":"35","author":"Saliba","year":"2022","journal-title":"Best Pract Res Clin Haematol"},{"issue":"7","key":"10.1053\/j.seminhematol.2026.04.003_bib0007","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1016\/j.mayocp.2017.05.010","article-title":"Leukemic transformation in myeloproliferative neoplasms: a literature review on risk, characteristics, and outcome","volume":"92","author":"Yogarajah","year":"2017","journal-title":"Mayo Clin Proc"},{"issue":"2","key":"10.1053\/j.seminhematol.2026.04.003_bib0008","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1038\/s41408-019-0175-y","article-title":"Leukemic transformation among 1306 patients with primary myelofibrosis: risk factors and development of a predictive model","volume":"9","author":"Vallapureddy","year":"2019","journal-title":"Blood Cancer J"},{"key":"10.1053\/j.seminhematol.2026.04.003_bib0009","doi-asserted-by":"crossref","DOI":"10.1111\/ejh.70141","article-title":"Risk of transformation to acute myeloid leukaemia and myelodysplastic syndromes in patients with myeloproliferative neoplasms over attained age and time since diagnosis: a nationwide cohort study","author":"Batyrbekova","year":"2026","journal-title":"Eur J Haematol"},{"issue":"5","key":"10.1053\/j.seminhematol.2026.04.003_bib0010","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1038\/s41375-018-0019-y","article-title":"Blast phase myeloproliferative neoplasm: Mayo-AGIMM study of 410 patients from two separate cohorts","volume":"32","author":"Tefferi","year":"2018","journal-title":"Leukemia"},{"key":"10.1053\/j.seminhematol.2026.04.003_bib0011","doi-asserted-by":"crossref","unstructured":"Nurse DP Outcomes of blast-phase MPN and JAK2, MPL, and CALR mutated de novo AML: a propensity score-adjusted cohort study. J Clin Oncol 2026:42. https:\/\/www.asco.org\/abstracts-presentations\/232593 [accessed 14.02.26]","DOI":"10.1200\/JCO.2024.42.16_suppl.6526"},{"issue":"13","key":"10.1053\/j.seminhematol.2026.04.003_bib0012","doi-asserted-by":"crossref","first-page":"3468","DOI":"10.1182\/bloodadvances.2024012880","article-title":"Treatment approach and outcomes of patients with accelerated\/blast-phase myeloproliferative neoplasms in the current era","volume":"8","author":"Patel","year":"2024","journal-title":"Blood Adv"},{"key":"10.1053\/j.seminhematol.2026.04.003_bib0013","unstructured":"Understanding triple negative myeloproliferative neoplasms: pathogenesis, clinical features, and management. https:\/\/www-tandfonline-com.yale.idm.oclc.org\/doi\/full\/10.1080\/10428194.2023.2277674 [accessed 25.01.26]"},{"issue":"14","key":"10.1053\/j.seminhematol.2026.04.003_bib0014","doi-asserted-by":"crossref","first-page":"2891","DOI":"10.1182\/blood-2009-08-236596","article-title":"Two routes to leukemic transformation after a JAK2 mutation\u2013positive myeloproliferative neoplasm","volume":"115","author":"Beer","year":"2010","journal-title":"Blood"},{"issue":"1","key":"10.1053\/j.seminhematol.2026.04.003_bib0015","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1001\/jamaoncol.2015.89","article-title":"Myeloproliferative neoplasms: a contemporary review","volume":"1","author":"Tefferi","year":"2015","journal-title":"JAMA Oncol"},{"key":"10.1053\/j.seminhematol.2026.04.003_bib0016","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1206965","article-title":"Epigenetics in myeloproliferative neoplasms","volume":"13","author":"Greenfield","year":"2023","journal-title":"Front Oncol"},{"issue":"3","key":"10.1053\/j.seminhematol.2026.04.003_bib0017","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1007\/s00277-017-3193-5","article-title":"Non-driver mutations in patients with JAK2V617F-mutated polycythemia vera or essential thrombocythemia with long-term molecular follow-up","volume":"97","author":"Sen\u00edn","year":"2018","journal-title":"Ann Hematol"},{"issue":"14","key":"10.1053\/j.seminhematol.2026.04.003_bib0018","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1182\/blood-2013-11-537167","article-title":"Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms","volume":"123","author":"Lundberg","year":"2014","journal-title":"Blood"},{"issue":"1","key":"10.1053\/j.seminhematol.2026.04.003_bib0019","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1182\/blood.2019000943","article-title":"Leukemia secondary to myeloproliferative neoplasms","volume":"136","author":"Dunbar","year":"2020","journal-title":"Blood"},{"issue":"50","key":"10.1053\/j.seminhematol.2026.04.003_bib0020","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.1407792111","article-title":"Genomic and functional analysis of leukemic transformation of myeloproliferative neoplasms","volume":"111","author":"Rampal","year":"2014","journal-title":"Proc Natl Acad Sci"},{"key":"10.1053\/j.seminhematol.2026.04.003_bib0021","doi-asserted-by":"crossref","unstructured":"Janus kinase 2 variants associated with the transformation of myeloproliferative neoplasms into acute myeloid leukemia. Cancer. 125(11):1855-1866. https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncr.31986 [accessed 17.02.26]","DOI":"10.1002\/cncr.31986"},{"issue":"23","key":"10.1053\/j.seminhematol.2026.04.003_bib0022","doi-asserted-by":"crossref","first-page":"3300","DOI":"10.1038\/onc.2016.478","article-title":"Loss of p53 induces leukemic transformation in a murine model of Jak2 V617F-driven polycythemia vera","volume":"36","author":"Tsuruta-Kishino","year":"2017","journal-title":"Oncogene"},{"issue":"24","key":"10.1053\/j.seminhematol.2026.04.003_bib0023","doi-asserted-by":"crossref","first-page":"3581","DOI":"10.1182\/bloodadvances.2018024018","article-title":"Advanced forms of MPNs are accompanied by chromosomal abnormalities that lead to dysregulation of TP53","volume":"2","author":"Marcellino","year":"2018","journal-title":"Blood Adv"},{"issue":"6","key":"10.1053\/j.seminhematol.2026.04.003_bib0024","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1038\/s41588-025-02190-6","article-title":"Chromothripsis-associated chromosome 21 amplification orchestrates transformation to blast-phase MPN through targetable overexpression of DYRK1A","volume":"57","author":"Brierley","year":"2025","journal-title":"Nat Genet"},{"issue":"Supplement 1","key":"10.1053\/j.seminhematol.2026.04.003_bib0025","doi-asserted-by":"crossref","first-page":"6657","DOI":"10.1182\/blood-2024-193917","article-title":"TP53 mutations and complex karyotype in newly-diagnosed blast\/accelerated phase MPN are associated with ephemeral response to treatment with venetoclax\u202f+\u202fHMA and poor survival","volume":"144","author":"Gangat","year":"2024","journal-title":"Blood"},{"issue":"4","key":"10.1053\/j.seminhematol.2026.04.003_bib0026","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1002\/ajh.27609","article-title":"TP53 Mutations in myeloproliferative neoplasms: context-dependent evaluation of prognostic relevance","volume":"100","author":"Tefferi","year":"2025","journal-title":"Am J Hematol"},{"key":"10.1053\/j.seminhematol.2026.04.003_bib0027","first-page":"1","article-title":"Risk stratification of patients with TP53-mutated myeloproliferative neoplasms","author":"Rolles","year":"2026","journal-title":"Leukemia"},{"issue":"2","key":"10.1053\/j.seminhematol.2026.04.003_bib0028","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1111\/bjh.20187","article-title":"Heterogeneity in outcomes of TP53-mutated myeloproliferative neoplasms based on disease phenotype and mutational status","volume":"207","author":"Badar","year":"2025","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminhematol.2026.04.003_bib0029","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2020.100711","article-title":"Role of inflammation in the biology of myeloproliferative neoplasms","volume":"42","author":"Koschmieder","year":"2020","journal-title":"Blood Rev"},{"issue":"1","key":"10.1053\/j.seminhematol.2026.04.003_bib0030","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1182\/hematology.2022000341","article-title":"Hitting the brakes on accelerated and blast-phase myeloproliferative neoplasms: current and emerging concepts","volume":"2022","author":"Bewersdorf","year":"2022","journal-title":"Hematology"},{"key":"10.1053\/j.seminhematol.2026.04.003_bib0031","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.molimm.2026.02.002","article-title":"Dynamic immune yin-yang in chronic myeloproliferative neoplasms mechanisms, therapeutic implications, and future directions","volume":"191","author":"Zhang","year":"2026","journal-title":"Mol Immunol"},{"issue":"9","key":"10.1053\/j.seminhematol.2026.04.003_bib0032","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1038\/s41588-023-01480-1","article-title":"Single-cell multi-omics identifies chronic inflammation as a driver of TP53-mutant leukemic evolution","volume":"55","author":"Rodriguez-Meira","year":"2023","journal-title":"Nat Genet"},{"issue":"4","key":"10.1053\/j.seminhematol.2026.04.003_bib0033","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","article-title":"Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel","volume":"129","author":"D\u00f6hner","year":"2017","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2026.04.003_bib0034","doi-asserted-by":"crossref","unstructured":"Genetic risk classification for adults with AML receiving less-intensive therapies: the 2024 ELN recommendations. Blood. 144:2169-2173. https:\/\/ashpublications.org\/blood\/article\/144\/21\/2169\/517356\/Genetic-risk-classification-for-adults-with-AML [accessed 16.02.26]","DOI":"10.1182\/blood.2024025409"},{"issue":"10","key":"10.1053\/j.seminhematol.2026.04.003_bib0035","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1182\/bloodadvances.2024015712","article-title":"Assessing AML-based risk criteria in patients with accelerated\/blast-phase MPN treated with less-intensive therapy","volume":"9","author":"Shaw","year":"2025","journal-title":"Blood Adv"},{"issue":"s1","key":"10.1053\/j.seminhematol.2026.04.003_bib0036","doi-asserted-by":"crossref","DOI":"10.3324\/haematol.2026.s1.15","article-title":"B07 | Molecular risk profiling in myeloproliferative neoplasms blast phase treated with venetoclax and decitabine: a three-gene score for survival prediction","volume":"111","author":"Crupi","year":"2026","journal-title":"Haematologica"},{"issue":"Supplement 1","key":"10.1053\/j.seminhematol.2026.04.003_bib0037","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1182\/blood-2025-1025","article-title":"Venetoclax and decitabine in myeloproliferative neoplasm-blast phase (MPN-BP): results of enable, a gimema and airc-mynerva multicenter, phase 2 trial","volume":"146","author":"Vannucchi","year":"2025","journal-title":"Blood"},{"issue":"2","key":"10.1053\/j.seminhematol.2026.04.003_bib0038","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1182\/blood-2005-10-4149","article-title":"Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia","volume":"108","author":"Cheson","year":"2006","journal-title":"Blood"},{"issue":"4","key":"10.1053\/j.seminhematol.2026.04.003_bib0039","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1182\/bloodadvances.2021006827","article-title":"Reduced intensity hematopoietic stem cell transplantation for accelerated-phase myelofibrosis","volume":"6","author":"Gagelmann","year":"2022","journal-title":"Blood Adv"},{"issue":"12","key":"10.1053\/j.seminhematol.2026.04.003_bib0040","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1016\/j.leukres.2012.08.013","volume":"36","author":"Mascarenhas","year":"2012","journal-title":"Leuk Res"},{"issue":"5","key":"10.1053\/j.seminhematol.2026.04.003_bib0041","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1182\/bloodadvances.2023011735","article-title":"Outcomes of intensive and nonintensive blast-reduction strategies in accelerated and blast-phase MPN","volume":"8","author":"Davidson","year":"2024","journal-title":"Blood Adv"},{"issue":"20","key":"10.1053\/j.seminhematol.2026.04.003_bib0042","doi-asserted-by":"crossref","first-page":"5246","DOI":"10.1182\/bloodadvances.2020002119","article-title":"Phase 2 study of ruxolitinib and decitabine in patients with myeloproliferative neoplasm in accelerated and blast phase","volume":"4","author":"Mascarenhas","year":"2020","journal-title":"Blood Adv"},{"issue":"4","key":"10.1053\/j.seminhematol.2026.04.003_bib0043","doi-asserted-by":"crossref","first-page":"828","DOI":"10.3324\/haematol.2023.283950","article-title":"Prevention and treatment of transformation of myeloproliferative neoplasms to acute myeloid leukemia","volume":"110","author":"Patel","year":"2024","journal-title":"Haematologica"},{"issue":"4","key":"10.1053\/j.seminhematol.2026.04.003_bib0044","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1002\/ajh.26833","article-title":"Outcomes after allogeneic hematopoietic cell transplant in patients diagnosed with blast phase of myeloproliferative neoplasms: a retrospective study from the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation","volume":"98","author":"Ort\u00ed","year":"2023","journal-title":"Am J Hematol"},{"issue":"21","key":"10.1053\/j.seminhematol.2026.04.003_bib0045","doi-asserted-by":"crossref","first-page":"5562","DOI":"10.1182\/bloodadvances.2020002727","article-title":"Genetic factors rather than blast reduction determine outcomes of allogeneic HCT in BCR-ABL\u2013negative MPN in blast phase","volume":"4","author":"Gupta","year":"2020","journal-title":"Blood Adv"},{"key":"10.1053\/j.seminhematol.2026.04.003_bib0046","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1182\/blood-2025-721","article-title":"Acute myeloid leukemia (AML) after myeloproliferative neoplasm (MPN): real-world outcomes in the new AML treatment era","volume":"146","author":"Bewersdorf","year":"2025","journal-title":"Blood"},{"issue":"8","key":"10.1053\/j.seminhematol.2026.04.003_bib0047","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/j.leukres.2015.03.001","article-title":"Azacytidine for the treatment of retrospective analysis from the Gruppo Laziale for the study of Ph-negative MPN","volume":"39","author":"Andriani","year":"2015","journal-title":"Leuk Res"},{"issue":"9","key":"10.1053\/j.seminhematol.2026.04.003_bib0048","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1016\/j.leukres.2015.06.001","article-title":"Therapeutic benefit of decitabine, a hypomethylating agent, in patients with high-risk primary myelofibrosis and myeloproliferative neoplasm in accelerated or blastic\/acute myeloid leukemia phase","volume":"39","author":"Badar","year":"2015","journal-title":"Leuk Res"},{"issue":"7","key":"10.1053\/j.seminhematol.2026.04.003_bib0049","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1002\/ajh.26186","article-title":"Venetoclax with azacitidine or decitabine in blast-phase myeloproliferative neoplasm: a multicenter series of 32 consecutive cases","volume":"96","author":"Gangat","year":"2021","journal-title":"Am J Hematol"},{"issue":"Supplement 1","key":"10.1053\/j.seminhematol.2026.04.003_bib0050","doi-asserted-by":"crossref","first-page":"3751","DOI":"10.1182\/blood-2025-3751","article-title":"Molecular predictors of survival in patients with myeloproliferative neoplasm-blast phase (MPN-BP) treated with venetoclax and decitabine","volume":"146","author":"Guglielmelli","year":"2025","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2026.04.003_bib0051","doi-asserted-by":"crossref","unstructured":"Chen J, Wang K, Xiao Z, Xu Z Efficacy and safety of combination therapies vs monotherapy of hypomethylating agents in accelerated or blast phase of Philadelphia negative myeloproliferative neoplasms: a systematic review and meta-analysis. Ann Med. 55(1):348-360. doi:10.1080\/07853890.2022.2164611","DOI":"10.1080\/07853890.2022.2164611"},{"issue":"21","key":"10.1053\/j.seminhematol.2026.04.003_bib0052","doi-asserted-by":"crossref","first-page":"5336","DOI":"10.1182\/bloodadvances.2020001528","article-title":"Outcome of patients with IDH1\/2-mutated post\u2013myeloproliferative neoplasm AML in the era of IDH inhibitors","volume":"4","author":"Chifotides","year":"2020","journal-title":"Blood Adv"},{"issue":"1","key":"10.1053\/j.seminhematol.2026.04.003_bib0053","doi-asserted-by":"crossref","DOI":"10.1111\/bjh.16709","article-title":"Clinical outcomes of IDH2-mutated advanced-phase Ph-negative myeloproliferative neoplasms treated with enasidenib","volume":"190","author":"Patel","year":"2020","journal-title":"Br J Haematol"},{"issue":"4","key":"10.1053\/j.seminhematol.2026.04.003_bib0054","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1111\/bjh.19944","article-title":"Olutasidenib demonstrates significant clinical activity in mutated IDH1 acute myeloid leukaemia arising from a prior myeloproliferative neoplasm","volume":"206","author":"De Botton","year":"2025","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminhematol.2026.04.003_bib0055","doi-asserted-by":"crossref","unstructured":"Gangat N, Ajufo H, Abdelmagid M, et al. IDH1\/2 inhibitor monotherapy in blast-phase myeloproliferative neoplasms: a multicentre experience. doi:10.1111\/bjh.19027","DOI":"10.1111\/bjh.19027"},{"issue":"2","key":"10.1053\/j.seminhematol.2026.04.003_bib0056","doi-asserted-by":"crossref","DOI":"10.1016\/j.bneo.2025.100089","article-title":"Response and outcomes of patients with IDH1\/2- mutated accelerated\/blast-phase myeloproliferative neoplasms","volume":"2","author":"Goldberg","year":"2025","journal-title":"Blood Neoplasia"},{"key":"10.1053\/j.seminhematol.2026.04.003_bib0057","series-title":"A phase 2 trial investigating decitabine in combination with a JAK-Inhibitor as a bridge to allogeneic hematopoietic stem cell transplant in patients with accelerated\/blast phase myeloproliferative neoplasms","year":"2025"},{"key":"10.1053\/j.seminhematol.2026.04.003_bib0058","series-title":"A phase 2 trial investigating the addition of pacritinib to a hypomethylating agent as a bridge to allogeneic hematopoietic stem cell transplant in patients with accelerated and blast phase myeloproliferative neoplasms","year":"2025"},{"key":"10.1053\/j.seminhematol.2026.04.003_bib0059","unstructured":"Mascarenhas J A Phase II open-label study of combined ruxolitinib and enasidenib in patients with accelerated\/blast-phase myeloproliferative neoplasm or chronic-phase myelofibrosis with an IDH2 mutation. clinicaltrials.gov; 2025. https:\/\/clinicaltrials.gov\/study\/NCT04281498 [accessed 23.12.25]"},{"key":"10.1053\/j.seminhematol.2026.04.003_bib0060","series-title":"A phase 1b trial of ivosidenib combined with ruxolitinib in IDH1-mutated advanced-phase MPNs","year":"2025"},{"key":"10.1053\/j.seminhematol.2026.04.003_bib0061","year":"2025","journal-title":"A Phase 2 study evaluating olutasidenib in combination with hypomethylating agents in patients with IDH1-mutated higher-risk myelodysplastic syndromes, chronic myelomonocytic leukemia, or advanced myeloproliferative neoplasm."},{"issue":"Supplement 1","key":"10.1053\/j.seminhematol.2026.04.003_bib0062","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1182\/blood-2025-484","article-title":"Safety and efficacy of the mutant calreticulin-specific monoclonal antibody INCA033989 as monotherapy or in combination with ruxolitinib in patients (pts) with myelofibrosis (MF): preliminary results from dose escalation of two global phase 1 studies","volume":"146","author":"Mascarenhas","year":"2025","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2026.04.003_bib0063","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1182\/blood-2025-1024","article-title":"Safety and efficacy of INCA033989, a novel first in class mutant calreticulin-specific monoclonal antibody, in patients with essential thrombocythemia","volume":"146","author":"Gupta","year":"2025","journal-title":"Blood"},{"issue":"7","key":"10.1053\/j.seminhematol.2026.04.003_bib0064","doi-asserted-by":"crossref","DOI":"10.1016\/S2352-3026(24)00132-7","article-title":"Iadademstat in combination with azacitidine in patients with newly diagnosed acute myeloid leukaemia (ALICE): an open-label, phase 2a dose-finding study","volume":"11","author":"Salamero","year":"2024","journal-title":"Lancet Haematol"},{"key":"10.1053\/j.seminhematol.2026.04.003_bib0065","series-title":"A randomized phase 2 trial of ASTX727 +\/- Iadademstat in accelerated\/blast-phase philadelphia chromosome-negative myeloproliferative neoplasms (MPNs","year":"2025"},{"issue":"3","key":"10.1053\/j.seminhematol.2026.04.003_bib0066","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1038\/leu.2016.260","article-title":"BET protein bromodomain inhibitor-based combinations are highly active against post-myeloproliferative neoplasm secondary AML cells","volume":"31","author":"Saenz","year":"2017","journal-title":"Leukemia"},{"issue":"Supplement 1","key":"10.1053\/j.seminhematol.2026.04.003_bib0067","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1182\/blood-2024-200925","article-title":"Safety and efficacy of bromodomain and extra-terminal inhibitor INCB057643 in patients with relapsed or refractory myelofibrosis and other advanced myeloid neoplasms: a phase 1 study","volume":"144","author":"Watts","year":"2024","journal-title":"Blood"},{"issue":"1","key":"10.1053\/j.seminhematol.2026.04.003_bib0068","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/s41408-022-00618-4","article-title":"Efficacy of CDK9 inhibition in therapy of post-myeloproliferative neoplasm (MPN) secondary (s) AML cells","volume":"12","author":"Fiskus","year":"2022","journal-title":"Blood Cancer J"},{"key":"10.1053\/j.seminhematol.2026.04.003_bib0069","unstructured":"AstraZeneca. A modular phase I\/II, open-label, multicentre study to assess AZD4573 in novel combinations with anti-cancer agents in patients with advanced haematological malignancies. clinicaltrials.gov; 2025. https:\/\/clinicaltrials.gov\/study\/NCT04630756 [accessed 15.12.26]"},{"issue":"4","key":"10.1053\/j.seminhematol.2026.04.003_bib0070","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1158\/1078-0432.CCR-19-1853","article-title":"AZD4573 is a highly selective CDK9 inhibitor that suppresses MCL-1 and induces apoptosis in hematologic cancer cells","volume":"26","author":"Cidado","year":"2020","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"issue":"18","key":"10.1053\/j.seminhematol.2026.04.003_bib0071","doi-asserted-by":"crossref","first-page":"10978","DOI":"10.1111\/jcmm.15730","article-title":"Bcl-xL represents a therapeutic target in Philadelphia negative myeloproliferative neoplasms","volume":"24","author":"Petiti","year":"2020","journal-title":"J Cell Mol Med"},{"issue":"13","key":"10.1053\/j.seminhematol.2026.04.003_bib0072","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1182\/blood.2021011094","article-title":"Erythroid\/megakaryocytic differentiation confers BCL-XL dependency and venetoclax resistance in acute myeloid leukemia","volume":"141","author":"Kuusanm\u00e4ki","year":"2023","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2026.04.003_bib0073","unstructured":"AbbVie. A phase 1 open-label study evaluating the safety and tolerability, and pharmacokinetics of navitoclax monotherapy and in combination with ruxolitinib in myeloproliferative neoplasm subjects. clinicaltrials.gov; 2025. https:\/\/clinicaltrials.gov\/study\/NCT04041050 [accessed 15.12.26]"},{"issue":"3","key":"10.1053\/j.seminhematol.2026.04.003_bib0074","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1182\/blood.2024027117","article-title":"Efficacy of a novel BCL-xL degrader, DT2216, in preclinical models of JAK2-mutated post-MPN AML","volume":"146","author":"Wang","year":"2025","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2026.04.003_bib0075","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1186\/s13045-025-01753-8","article-title":"First in human phase 1 study of DT2216, a selective BCL-xL degrader, in patients with relapsed\/refractory solid malignancies","volume":"18","author":"Mahadevan","year":"2025","journal-title":"J Hematol OncolJ Hematol Oncol"}],"container-title":["Seminars in Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0037196326000296?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0037196326000296?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T04:58:41Z","timestamp":1792126721000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0037196326000296"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":75,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S0037196326000296"],"URL":"https:\/\/doi.org\/10.1053\/j.seminhematol.2026.04.003","relation":{},"ISSN":["0037-1963"],"issn-type":[{"value":"0037-1963","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Current landscape and future directions for treatment of accelerated-phase and blast-phase myeloproliferative neoplasms","name":"articletitle","label":"Article Title"},{"value":"Seminars in Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.seminhematol.2026.04.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}